PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study

被引：1

作者：

Pascual, T. ^{[1
]}

Bermejo De Las Heras, B. ^{[2
]}

Martinez, N. ^{[3
]}

Oliveira, M. ^{[4
]}

Pernas Simon, S. ^{[5
]}

Lopez Lopez, R. ^{[6
]}

Ruiz Cabrero, I. ^{[7
]}

Alarcon, J. D. ^{[8
]}

Martinez De Duenas, E. ^{[9
]}

Malon Gimenez, D. ^{[10
]}

Gonzalez Cao, M. ^{[11
]}

Manso Sanchez, L. M. ^{[12
]}

Morales Murillo, S. ^{[13
]}

Lopez de Ceballos, H. ^{[14
]}

Cortes, J. ^{[15
]}

Llombart Cussac, A. ^{[16
]}

Prat, A. ^{[17
]}

机构：

[1] Hosp Clin Barcelona, Dept Clin Res, SOLTI Canc Res Grp, Barcelona, Spain

[2] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[3] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain

[4] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[5] ICO Inst Catala Oncol Hosp Hosp Duran, Med Oncol Breast Unit, Lhospitalet De Llobregat, Spain

[6] CHUS Complejo Hosp Univ Santiago Composte, Dept Med Oncol, La Coruna, Spain

[7] Hosp Santa Tecla, Dept Med Oncol, Tarragona, Spain

[8] Hosp Univ Son Espases, Dept Med Oncol, Palma De Mallorca, Spain

[9] Hosp Prov Castellon, Med Oncol, Castellon De La Plana, Spain

[10] Hosp Univ Fuenlabrada, Dept Med Oncol, Fuenlabrada, Spain

[11] Hosp Univ Dexeus, Med Oncol, Barcelona, Spain

[12] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[13] Hosp Arnau Vilanova Lleida, Dept Med Oncol, Alpicat, Spain

[14] Hosp San Pedro Alcantara, Med Oncol, Caceres, Spain

[15] VHIO Valle Hebron Inst Oncol, Dept Oncol, Barcelona, Spain

[16] Hosp Arnau Vilanova, Dept Med Oncol, Valencia, Spain

[17] Hosp Clin Prov & Barcelona, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.03.111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

95P

引用

页码：S168 / S168

页数：1

共 50 条

[1] PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer
Vidal, M.
de la Pena, L.
Oliveira, M.
Cortes, J.
Llombart, A.
Prat, A.
CANCER RESEARCH, 2013, 73
[2] PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.
Vidal, Maria
De La Pena, Lorena
Oliveira, Mafalda
Cortes, Javier
Llombart, Antonio
Prat, Aleix
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis
Schettini, F.
Pascual, T.
Chic, N.
Conte, B.
Martinez, O.
Adamo, B.
Vidal, M.
Munoz, M.
Fernandez-Martinez, A.
Griguolo, G.
Guarneri, V.
Conte, P. F.
De Placido, S.
Carey, L.
Perou, C. M.
Prat, A.
ANNALS OF ONCOLOGY, 2019, 30
[4] PAM50 HER2-Enriched Subtype Enriches for Tumor Response to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane Containing Regimens in HER2-Positive Breast Cancer.
Cheang, M. C. U.
Prat, A.
Fan, C.
Perou, C. M.
CANCER RESEARCH, 2011, 71
[5] PAM50 intrinsic subtyping as a predictor of pathological complete response to neoadjuvant trastuzumab-based chemotherapy in early HER2-positive breast cancer
Pernas, Sonia
Petit, Anna
Climent, Fina
Pare, Laia
Perez-Martin, Javier
Ventura, Luz
Galvan, Patricia
Falo, Catalina
Morilla, Idoia
Fernandez-Ortega, Adela
Stradella, Agostina
Pascual, Tomas
Gil-Gil, Miguel
Prat, Aleix
CANCER RESEARCH, 2018, 78 (04)
[6] Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer
Braso-Maristany, F.
Griguolo, G.
Llombart-Cussac, A.
Pascual, T.
Pare, L.
Bermejo, B.
Oliveira, M.
Morales, S.
Martinez, N.
Vidal, M.
Pernas, S.
Lopez, R.
Munoz, M.
Galvan, P.
Garau, I.
Manso, L.
Alarcon, J.
Martinez, E.
Villagrasa, P.
Cortes, J.
Prat, A.
CANCER RESEARCH, 2019, 79 (04)
[7] Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer
Prat, Aleix
De Angelis, Carmine
Pascual, Tomas
Gutierrez, Carolina
Wang, Tao
Pare, Laia
Rexer, Brent
Cortes, Javier
Forero, Andres
Llombart, Antonio
Wolff, Antonio C.
Krop, Ian
Galvan, Patricia
Pavlick, Anne C.
Villagrasa, Patricia
Hilsenbeck, Susan G.
Schiff, Rachel
Osborne, C. Kent
Rimawi, Mothaffar F.
CANCER RESEARCH, 2018, 78 (04)
[8] PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial
Aparicio, A. Prat
Castan, J. Cortes
Pare, L.
Galvan, P.
Bermejo, B.
Martinez, N.
Vidal, M.
Pernas, S.
Lopez, R.
Munoz, M.
Nuciforo, P.
Fasani, R.
Morales, S.
Oliveira, M.
de la Pena, L.
Pelaez, A.
Llombart, A.
CANCER RESEARCH, 2017, 77
[9] Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA
Batistella, Enzo
Pare, Laia
Sahasrabudhe, Mihir
Pascual, Tomas
Vakalopoulou, Maria
Villagrasa, Patricia
Deutsch, Eric
Chic, Nuria
Villacampa, Guillermo
Nuciforo, Paolo
Cortes, Javier
Llombart-Cussac, Antonio
Paragios, Nikos
Prat, Aleix
CANCER RESEARCH, 2021, 81 (04)
[10] PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
Conte, Pier Franco
Griguolo, Gaia
Dieci, Maria Vittoria
Bisagni, Giancarlo
Brandes, Alba Ariela
Frassoldati, Antonio
Cavanna, Luigi
Musolino, Antonino
Giotta, Francesco
Rimanti, Anita
Garrone, Ornella
Galvan, Patricia
Maristany, Fara Braso
Orvieto, Enrico
Urso, Loredana
Maiorana, Antonino
Balduzzi, Sara
D'Amico, Roberto
Guarneri, Valentina
Prat, Aleix
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →